» Articles » PMID: 15592509

The AKT/I Kappa B Kinase Pathway Promotes Angiogenic/metastatic Gene Expression in Colorectal Cancer by Activating Nuclear Factor-kappa B and Beta-catenin

Overview
Journal Oncogene
Date 2004 Dec 14
PMID 15592509
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

Our laboratory has delineated that the phosphatidylinositol 3' kinase (PI3K)/AKT/I kappa B kinase (IKK) pathway positively regulates NF kappa B and beta-catenin, both important transcriptional regulators in colorectal cancer (CRC). Therefore, we investigated the effect of inhibiting the PI3K/AKT/IKK alpha pathway in regulating the inappropriate constitutive activation of NF kappa B and beta-catenin in CRC cell lines. SW480 and RKO CRC cell lines demonstrate constitutive activation of AKT as well as both NF kappa B- and beta-catenin-dependent transcription. The constitutive activation of NF kappa B- and beta-catenin-dependent transcription is inhibited by transiently transfecting either kinase dead (KD) IKK alpha, which blocks IKK alpha kinase activity, KD AKT, which blocks AKT activity, or wildtype (WT) PTEN, which inhibits PI3K and AKT activity. The ability of KD IKK alpha, KD AKT or WT PTEN to decrease beta-catenin-dependent transcription is independent of their effects on NF kappa B. Inducible expression of either KD IKK alpha or WT PTEN strongly inhibits both the constitutive NF kappa B- and beta-catenin-dependent promoter and endogenous gene activation. Targeted array-based gene expression analysis of this inducible system reveals that many of the genes downregulated upon inhibition of this pathway are involved in tumor angiogenesis and metastasis. The activation of this pathway and the expression of the three most repressed genes was further analysed in samples of CRC. These results indicate a role of this pathway in controlling gene expression important in tumor progression and metastasis.

Citing Articles

Angel or devil: the dual roles of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucopyranoside in the development of liver injury based on integrating pharmacological techniques: a systematic review.

Jiang J, Wang Q, Wu Q, Deng B, Guo C, Chen J Front Pharmacol. 2025; 16:1523713.

PMID: 39963244 PMC: 11830817. DOI: 10.3389/fphar.2025.1523713.


ArfGAP with the SH3 Domain, Ankyrin Repeat and PH Domain 1 Inversely Regulates Programmed Death-Ligand 1 Through Negative Feedback of Phosphorylated Epithelial Growth Factor Receptor and Activation of Nuclear Factor-Kappa B in Non-Small Cell Lung....

Chiba N, Menju T, Shimazu Y, Toyazaki T, Sumitomo R, Miyamoto H Cancer Manag Res. 2025; 17:91-102.

PMID: 39866192 PMC: 11759582. DOI: 10.2147/CMAR.S493368.


NF-κB pathway and angiogenesis: insights into colorectal cancer development and therapeutic targets.

Bahrami A, Khalaji A, Najafi M, Sadati S, Raisi A, Abolhassani A Eur J Med Res. 2024; 29(1):610.

PMID: 39702532 PMC: 11658081. DOI: 10.1186/s40001-024-02168-w.


Zebrafish drug screening identifies Erlotinib as an inhibitor of Wnt/β-catenin signaling and self-renewal in T-cell acute lymphoblastic leukemia.

Al-Hamaly M, Cox A, Haney M, Zhang W, Arvin E, Sampathi S Biomed Pharmacother. 2023; 170:116013.

PMID: 38104416 PMC: 10833092. DOI: 10.1016/j.biopha.2023.116013.


Regulation of Vascular Endothelial Growth Factor Signaling by Nicotine in a Manner Dependent on Acetylcholine-and/or β-Adrenergic-Receptors in Human Lung Cancer Cells.

Al Khashali H, Darweesh B, Ray R, Haddad B, Wozniak C, Ranzenberger R Cancers (Basel). 2023; 15(23).

PMID: 38067204 PMC: 10705358. DOI: 10.3390/cancers15235500.